Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On May 16, 2025, Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock at a weighted average price of $11.31 per share.
- On May 19, 2025, Mr. Ma sold another 2,000 shares of common stock at a weighted average price of $11.11 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these sales, Mr. Ma indirectly owns 2,814,824 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Sales by company presidents are common and are often pre-planned to avoid insider trading accusations. The use of a 10b5-1 trading plan is a standard practice for executives to sell shares over time.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 05/16/2025 | Sale of 2,000 shares of common stock |
| 05/19/2025 | Sale of 2,000 shares of common stock |
| 05/20/2025 | Date of Form 4 filing |
Keywords
Form 4, Gyre Therapeutics, Songjiang Ma, stock sale, 10b5-1 trading plan, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.